1. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Nishimura M, Hayashi M, Mizutani Y, Takenaka K, Imamura Y, Chayahara N, Toyoda M, Kiyota N, Mukohara T, Aikawa H, Fujiwara Y, Hamada A, Minami H. Oncotarget. 2018, 9(26):18540-18547.
2. Ryu S, Hayashi M, Aikawa H, Okamoto I, Fujiwara Y, Hamada A. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study. Br J Pharmacol. 2018, 175(1):29-37.
3. Nishidate M, Yamamoto K, Masuda C, Aikawa H, Hayashi M, Kawanishi T, Hamada A. MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells. Sci Rep. 2017,7(1):16763.
4. Tsubata Y, Hayashi M, Tanino R, Aikawa H, Ohuchi M, Tamura K, Fujiwara Y, Isobe T, Hamada A. Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. Sci Rep. 2017, 7(1):12622.
5. 質量分析イメージングを用いた薬物定量の現状. 鍛治 秀文、林 光博、相川 博明、西館 正修、濱 田 哲暢、臨床化学、46、291-298、2017
6. 抗がん剤結合抗体. 林 光博、濱田 哲暢、田村 研治、腫瘍内科、9、392-396、2017